Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF)
- Avricore Health signed the first amendment to its supplier distribution agreement between subsidiary HealthTab and Abbott
- The amendment adds to the agreement Abbott’s ID Now(TM) molecular testing device, which will bring in onsite testing and reporting capabilities for SARS-CoV-2 (Covid-19), RSV, Influenza A & B, and Strep
- Avricore also announced its partnership with Ellerca Health, which will see the companies use their respective technologies (Avricore’s HealthTab and Ellerca’s 360Care app) to support patient needs at community pharmacy level
recently made several key strides in its quest to become the world’s leader point-of-care technologies within community pharmacy. On July 26, the company announced the signing of the first amendment to its supplier distribution agreement between its wholly owned subsidiary and flagship offering, HealthTab(TM) Inc, and Abbott (NYSE: ABT)
, the global healthcare company and diagnostics leader, in Canada (https://ibn.fm/5IKuw
Under the original supplier distribution agreement, first signed on May 31 this year (https://ibn.fm/oWz8Y
), HealthTab received the mandate to distribute in Canada Abbott’s Afinion(TM) 2 – a small, fast, and multi-assay analyzer providing valuable point-of-care testing to patients – and associated tests for diabetes and heart-disease screening in community pharmacies, including HbA1c testing – also known as A1C.
A few days later, Avricore signed the Master Agreement with Canada’s largest pharmacy network, Shoppers Drug Mart, that would enable patients to access its HealthTab platform – an innovative point-of-care blood screening and health-data management platform – integrated with Abbott’s Afinion 2 analyzers. The company has since completed a test rollout of its platform in which over 600 results were reported in the week-and-a-half trial period (https://ibn.fm/DDwar
Following the test rollout, a pharmacist and associate owner of a Shoppers Drug Mart located in Mississauga, Ontario, expressed his excitement at having HealthTab in his store because the platform would demonstrate a new, better way of doing pharmacy practice. “This is really profound because having access to lab-accurate results at our fingertips means we can better help family physicians by conducting regular follow up using advanced diagnostics with our diabetic and cardiovascular patients more effectively,” Mohamed Adel Elsabakhawi had said (https://ibn.fm/lcdQ9
In what will surely expand the capabilities of pharmacists like Mohamed in addition to helping detect infections before they spread, the first amendment adds to the distribution agreement Abbott’s ID Now(TM) molecular testing device, which will introduce onsite testing and reporting capabilities for SARS-CoV-2, RSV, Influenza A & B, and Strep.
“A missing link today in the response to COVID-19 and general virus outbreak is the ability to get confirmatory testing and reliable, real-time reporting in a low-barrier setting,” said Avricore CEO Hector Bremner. “With ID Now on the HealthTab network in community pharmacy, patients can know what they have and get focused treatment and prevent spread through better information.”
Avricore, which expects to add more analyzers and testing capabilities, also signed a partnership agreement with Ellerca Health Corp, a Toronto, Canada-based digital health organization revolutionizing the personal experience and health outcomes of people living with chronic diseases (https://ibn.fm/1EteR
The mutual collaboration on a project-by-project basis will see the companies use Avricore’s HealthTab and Ellerca’s 360Care(TM) to support patients’ needs at the community pharmacy level. The technologies will prioritize early detection, screening, and the consistent management of chronic diseases, like diabetes, as well as support better health outcomes for people living with these conditions. The partnership will, for instance, allow Ellerca’s members to easily access A1C testing at local pharmacies and improve the speed of results.
The 360Care is a supportive, app-based digital platform that facilitates self-management of chronic diseases and allows patients to be in control of their own treatment. By working together with patients in this way, the platform lowers the time and cost of reactionary treatments and shifts the focus to preventative care by reducing and eliminating symptoms of chronic conditions.
Avricore and Ellerca are looking forward to bringing to community pharmacy enhanced patient services that combine HealthTab’s diagnostics and data-management systems with the ongoing coaching and support of 360Care.
For more information, visit the company’s website at www.AvricoreHealth.com
NOTE TO INVESTORS:
The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.